Pharmacovigilance
Weekly PV Briefing — Cosentyx
Week ending 30 August 2026
Scope: internal monitoring of third-party AI-generated content. These observations are not adverse-event reports and do not constitute a confirmed safety signal.
1. Signal summary
There were 29 cross-response inconsistency flags, up from 26 last week (+3), despite 20 fewer responses. This is the highest flag count in the available rolling history since 26 July and indicates increased inconsistency density.
The category tally below reflects raw response tagging, not confirmed safety events or necessarily inconsistency flags:
- Hedging/disclaimer: 98 (−22)
- Infection risk: 75 (−12)
- IBD: 32 (−8)
- Overclaim language: 29 (−4)
- Contraindication: 23 (−3)
- Allergic reaction: 17 (−6)
- Pregnancy/lactation: 17 (−2)
- Pediatric: 16 (−1)
- Dosing-specific: 15 (−5)
- Biosimilar/generic: 11 (flat)
- Boxed warning: 6 (−2)
- Kidney impairment: 6 (flat)
Thus, overall safety-category tagging is generally falling, but cross-answer inconsistency is rising.
2. Highest-priority inconsistencies
-
Boxed warnings question (PI; query 220): boxed-warning content was mentioned in 5 variants and omitted in 1. One variant stated that Cosentyx carries a boxed warning, while others stated that it does not. This conflicting classification could materially alter perceived urgency and treatment decision-making; verify all variants against the current applicable PI.
-
Active infection—starting or continuing treatment (PI; query 221): contraindication/not-recommended language appeared in 1 variant and was omitted in 5; IBD content also appeared in 1 and was omitted in 5. An answer could therefore fail to clearly direct a patient with an active infection to seek prescriber assessment before initiating or continuing therapy.
-
Marketing versus clinical guidance (brand; query 235): allergic-reaction information appeared in 1 variant and was omitted in 5; pregnancy/lactation information appeared in 1 and was omitted in 5; contraindication language appeared in 4 and was omitted in 2. Consumer-facing answers may present benefit-oriented framing without consistently surfacing clinically important limitations and precautions.
-
Administration and injection handling (PI; query 218): allergic-reaction content appeared in 2 variants and was omitted in 4; infection-risk content appeared in 2 and was omitted in 4. Patients receiving device instructions may not consistently receive relevant stop/seek-help precautions.
-
Cosentyx versus Humira for psoriasis (brand; query 226): allergic-reaction information appeared in 1 variant and was omitted in 5. A patient-directed comparison focused on effectiveness and side effects could consequently provide an incomplete safety picture.
3. Recurring or worsening themes
No category tally is rising across multiple consecutive weeks. However, infection-risk and IBD content remain recurrent high-volume themes, and contraindication/allergic-reaction omissions recur across multiple PI and consumer questions. The total inconsistency count has risen from 24 to 26 to 29 over the last three weeks, warranting continued focused review.
4. Escalation recommendation
Flag to a human safety/medical reviewer this week. Priority review is warranted for the boxed-warning contradiction and repeated contraindication, allergic-reaction, infection, and pregnancy/lactation omissions. This is a pattern in AI-generated content—not evidence of a confirmed product safety signal. Other lower-severity informational gaps should be logged and monitored.
5. Recommended actions
- Validate query 220 variants against the current regional PI and document the boxed-warning discrepancy.
- Perform medical/regulatory review of queries 221, 218, and 225 for label-accurate safety wording.
- Review consumer comparison prompts 226 and 235 for consistent presentation of key precautions.
- Add these topic pairs to next week’s targeted re-query set, including live-vaccine and pregnancy/lactation details.
- Log the rising inconsistency trend for the next PV–Medical/Regulatory Affairs sync.